Impact of body weight on efficacy of tildrakizumab in moderate to severe plaque psoriasis

被引：0

作者：

Leonardi, Craig ^{[1
,2
]}

Menter, Alan M. ^{[3
,4
]}

Draelos, Zoe ^{[5
]}

Heim, Jayme ^{[6
]}

Parno, Jeff ^{[7
]}

Mendelsohn, Alan M. ^{[7
]}

Rozzo, Stephen J. ^{[7
]}

Griffiths, Christopher E. M. ^{[8
]}

机构：

[1] Cent Dermatol, St Louis, MO USA

[2] St Louis Univ, Sch Med, St Louis, MO USA

[3] Baylor Scott & White, Div Dermatol, Dallas, TX USA

[4] Texas A&M Coll Med, Dallas, TX USA

[5] Dermatol Consulting Serv, High Point, NC USA

[6] West Michigan Dermatol, Holland, MI USA

[7] Sun Pharmaceut Ind Inc, Princeton, NJ USA

[8] Univ Manchester, Salford Royal NHS Fdn Trust, Dermatol Ctr, Manchester, Lancs, England

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2019年 / 81卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

10089

引用

页码：AB76 / AB76

页数：1

共 50 条

[41] COST EFFICACY OF USTEKINUMAB IN TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN TURKEY
Tatar, M.
Sarioz, F.
VALUE IN HEALTH, 2010, 13 (03) : A146 - A147
[42] Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore
Chan, Wai Sze Agnes
Wong, Yisheng
Oon, Hazel Hwee Boon
Theng, Colin Thiam Seng
Chong, Wei-Sheng
SINGAPORE MEDICAL JOURNAL, 2023, 64 (07) : 434 - 438
[43] Remicade® in moderate to severe plaque psoriasis
Ortonne, J. -P.
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2006, 133 (05): : 1S13 - 1S17
[44] Efficacy and safety of long-term tildrakizumab for moderate to severe chronic plaque psoriasis: 3-year results from reSURFACE 2
Gooderham, M.
Papp, K.
Blauvelt, A.
Thaci, D.
Li, Q.
Mendelsohn, A.
Parno, J.
Reich, K.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 61 - 62
[45] Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice
Hung, Yi-Teng
Lin, Yu-, Jr.
Chiu, Hsien-Yi
Huang, Yu-Huei
THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2021, 12
[46] Safety of tildrakizumab in a Phase 4 real-world study in patients with moderate-to-severe plaque psoriasis
Vasquez, J. Gabriel
Bhatia, Neal
Schenkel, Brad
Rozzo, Stephen J.
Heim, Jayme
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB85 - AB85
[47] Efficacy of adalimumab is consistent across body weight in patients with moderate to severe psoriasis: Subanalysis of REVEAL
Leonardi, C.
Chen, K.
Gordon, K.
Goldblum, O.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB158 - AB158
[48] Efficacy and safety of long-term tildrakizumab for moderate to severe chronic plaque psoriasis: 3-year results from reSURFACE 1
Tyring, S.
Spelman, L.
Igarashi, A.
Ohtsuki, M.
Li, Q.
Mendelsohn, A.
Parno, J.
Guenthner, S.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 61 - 61
[49] Interim Analysis of the non-interventional Study TILOT: Efficacy of Tildrakizumab for the Treatment of Patients with moderate to severe Plaque Psoriasis under Practical Conditions
Tsianakas, A.
Kirsch, A.
Diemert, S.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 39 - 39
[50] Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis
Feldman, Steven R.
Merola, Joseph F.
Pariser, David M.
Zhang, Jingchuan
Zhao, Yang
Mendelsohn, Alan M.
Gottlieb, Alice B.
JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (03) : 1670 - 1675

← 1 2 3 4 5 →